Daxor Corporation (DXR)
- Previous Close
9.71 - Open
9.65 - Bid --
- Ask --
- Day's Range
9.65 - 9.65 - 52 Week Range
7.11 - 13.13 - Volume
502 - Avg. Volume
2,442 - Market Cap (intraday)
46.381M - Beta (5Y Monthly) -0.44
- PE Ratio (TTM)
68.93 - EPS (TTM)
0.14 - Earnings Date Mar 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 5, 2018
- 1y Target Est
23.25
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
www.daxor.comRecent News: DXR
Performance Overview: DXR
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DXR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DXR
Valuation Measures
Market Cap
46.38M
Enterprise Value
--
Trailing P/E
68.93
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
36.22
Price/Book (mrq)
1.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
171.73%
Return on Assets (ttm)
-1.51%
Return on Equity (ttm)
0.89%
Revenue (ttm)
163.42k
Net Income Avi to Common (ttm)
280.64k
Diluted EPS (ttm)
0.14
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
2.22%
Levered Free Cash Flow (ttm)
161.1k